Telavancin, a hope against Methicillin Resistant Staphylococcus aureus

Authors

  • Nazish Babar Department of Microbiology, Fazaia Medical College, Air University, Islamabad
  • Mushtaq Gill Department of Microbiology, CMH, Lahore
  • Mehreen Gilani Department of Microbiology Army Medical College, Rawalpindi
  • Javaid Usman Department of Microbiology, Quetta Institute of Medical Sciences
  • Hijab Shah Department of Pathology, Fazaia Medical College, Air University, Islamabad

Keywords:

MRSA, Telavancin, VISA and VRSA

Abstract

Objective: To determine the in vitro efficacy of Telavancin against Methicillin resistant Staphylococcus aureus.

Methods: This cross-sectional study was conducted at the Department of Microbiology, Army Medical College, Islamabad/Military Hospital, Rawalpindi, from 1st Nov 2012 to 30th June 2013. The authors aimed at assessing the in vitro efficacy of Telavancin against Methicillin resistant Staphylococcus aureus by E strip method as this study will be a help in determining guidelines for the interpretation of our local susceptibility breakpoint criteria for Telavancin against possibly emerging vancomycin intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Should vancomycin resistance become wide spread alternative therapies for methicillin resistant Staphylococcus aureus will be urgently needed.

Results: In this study 102 methicillin resistant Staphylococcus aureus were isolated, and all were found to be 100% susceptible to Telavancin.

Conclusion: Telavancin has excellent in vitro activity against methicillin resistant Staphylococcus aureus

Downloads

Published

2019-10-01

Issue

Volume.17, Issue-2 (Apr-Jun 2019)

Section

Original article

License

Copyright (c) 2019 Nazish Babar; Mushtaq Gill, Mehreen Gilani, Javaid Usman, Hijab Shah

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

How to Cite

1.
Babar N. Telavancin, a hope against Methicillin Resistant Staphylococcus aureus. Int J Pathol [Internet]. 2019 Oct. 1 [cited 2024 Nov. 22];17(2):57-61. Available from: https://jpathology.com/index.php/OJS/article/view/440

Most read articles by the same author(s)